Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Plus Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HOUSTON, JULY 31, 2026 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ: PSTV) (THE COMPANY), TODAY ANNOUNCES THAT ITS CORPORATE REBRAND TO CERENOME WILL BE COMPLETED AS SCHEDULED. EFFECTIVE AUGUST 3, 2026, THE COMPANY'S NAME WILL BECOME CERENOME, INC. THE COMPANY'S COMMON STOCK WILL BEGIN TRADING ON THE NASDAQ CAPITAL MARKET UNDER THE NEW TICKER SYMBOL CNSY, EFFECTIVE MARKET OPEN ON THE SAME DAY.

CERENOME LAUNCHES AS AN INTEGRATED CNS ONCOLOGY COMPANY

HOUSTON, JULY 28, 2026 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC.(NASDAQ: PSTV) (THE COMPANY), A HEALTHCARE COMPANY DEVELOPING AND COMMERCIALIZING TARGETED THERAPEUTICS AND DIAGNOSTICS FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY ANNOUNCED TWO POSTERS HIGHLIGHTING ITS RESPECT-LM CLINICAL DEVELOPMENT PROGRAM AND CNSIDE CEREBROSPINAL FLUID (CSF) DIAGNOSTIC PLATFORM WILL BE PRESENTED AT THE 2026 SOCIETY FOR NEURO-ONCOLOGY/AMERICAN SOCIETY OF CLINICAL ONCOLOGY (SNO/ASCO) CNS METASTASES CONFERENCE, BEING HELD AUGUST 1315, 2026, IN BOSTON, MASSACHUSETTS. THE COMPANY AND ITS WHOLLY OWNED SUBSIDIARY, CNSIDE DIAGNOSTICS, LLC, WILL ALSO HOST A SPONSORED SYMPOSIUM TITLED REDEFINING THE MANAGEMENT OF LEPTOMENINGEAL METASTASES: INTEGRATING DIAGNOSTICS, MOLECULAR INSIGHTS, AND EMERGING THERAPIES ON THURSDAY EVENING, AUGUST 13, 2026.

PLUS THERAPEUTICS ANNOUNCES SCIENTIFIC PRESENTATIONS AND SPONSORED SYMPOSIUM AT 2026 SNO/ASCO CNS METASTASES CONFERENCE

HOUSTON, JULY 21, 2026 (GLOBE NEWSWIRE) -- CNSIDE DIAGNOSTICS, LLC, A WHOLLY-OWNED SUBSIDIARY OF PLUS THERAPEUTICS, INC. (NASDAQ: PSTV ) (PLUS OR THE COMPANY), ANNOUNCED TODAY THAT IT HAS SIGNED A REGIONAL AGREEMENT WITH MEDICAL MUTUAL EFFECTIVEJULY 1, 2026, COVERING APPROXIMATELY 1.2 MILLION PEOPLE THROUGHOUTOHIO AND KENTUCKY, TO PROVIDE THE CNSIDE CEREBROSPINAL FLUID (CSF) TUMOR CELL ENUMERATION (TCE) ASSAY. THIS BRINGS CNSIDE CSF TCE ASSAY TOTAL CONTRACTED COVERAGE TO APPROXIMATELY 127 MILLION PEOPLE.

PLUS THERAPEUTICS SECURES REGIONAL COVERAGE AGREEMENT WITH MEDICAL MUTUAL FOR CNSIDE CEREBROSPINAL FLUID ASSAY FOR METASTATIC CNS CANCER

COLLABORATION EXPECTED TO DELIVER HUNDREDS OF DNA AND RNA BIOMARKERS FROM A SINGLE CSF SPECIMEN  DIRECTLY ALIGNED WITH THE UPDATED NCCN GUIDELINES (VERSION 2.2026), WHICH NOW RECOGNIZE CSF CIRCULATING TUMOR CELLS ALONGSIDE TUMOR-DERIVED DNA AND BROADEN THE LEPTOMENINGEAL TREATMENT ALGORITHM FROM CSF CYTOLOGY TO CSF ANALYSIS COLLABORATION EXPECTED TO DELIVER HUNDREDS OF DNA AND RNA BIOMARKERS FROM A SINGLE CSF SPECIMEN  DIRECTLY ALIGNED WITH THE UPDATED NCCN GUIDELINES (VERSION 2.2026), WHICH NOW RECOGNIZE CSF CIRCULATING TUMOR CELLS ALONGSIDE TUMOR-DERIVED DNA AND BROADEN THE LEPTOMENINGEAL TREATMENT ALGORITHM FROM CSF CYTOLOGY TO CSF ANALYSIS

PLUS THERAPEUTICS AND GENOMIC TESTING COOPERATIVE PARTNER TO INTEGRATE NEXT-GENERATION SEQUENCING INTO THE CNSIDE CSF ASSAY PLATFORM

UPDATED NCCN LANGUAGE CONTINUES TO SUPPORT CSF ANALYSIS IN THE DIAGNOSIS AND MANAGEMENT OF LEPTOMENINGEAL METASTASES, INCLUDING CSF CYTOLOGY FOLLOW-UP EVERY 4 TO 8 WEEKS FOR PATIENTS RECEIVING INTRATHECAL THERAPY, TO ENABLE LONGITUDINAL PATIENT MONITORING UPDATED NCCN LANGUAGE CONTINUES TO SUPPORT CSF ANALYSIS IN THE DIAGNOSIS AND MANAGEMENT OF LEPTOMENINGEAL METASTASES, INCLUDING CSF CYTOLOGY FOLLOW-UP EVERY 4 TO 8 WEEKS FOR PATIENTS RECEIVING INTRATHECAL THERAPY, TO ENABLE LONGITUDINAL PATIENT MONITORING

PLUS THERAPEUTICS HIGHLIGHTS NCCN CNS CANCERS GUIDELINES UPDATE AND REINFORCES CLINICAL ROLE OF CNSIDE IN LEPTOMENINGEAL METASTASES MONITORING

PLUS THERAPEUTICS TO BECOME CERENOME, TO TRADE UNDER NEW NASDAQ TICKER CNSY ON AUGUST 3, 2026 AFFIRMS 2026 GUIDANCE ON KEY MILESTONES REPORTS POSITIVE CNSIDE COMMERCIAL PROGRESS HOUSTON, JUNE 30, 2026 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ: PSTV) (PLUS OR THE COMPANY), A HEALTHCARE COMPANY FOCUSED ON CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY PROVIDES A COMPREHENSIVE BUSINESS UPDATE. NOTABLY, THE COMPANY ANNOUNCES IT IS CHANGING ITS COMPANY NAME FROM PLUS THERAPEUTICS TO CERENOME AND NASDAQ TICKER TO CNSY, EFFECTIVE AUGUST 3, 2026.

PLUS THERAPEUTICS PROVIDES MID-YEAR BUSINESS UPDATE INCLUDING CORPORATE REBRANDING

HOUSTON, JUNE 25, 2026 (GLOBE NEWSWIRE) -- CNSIDE DIAGNOSTICS, LLC, A WHOLLY-OWNED SUBSIDIARY OF PLUS THERAPEUTICS, INC. (NASDAQ: PSTV) (PLUS OR THE COMPANY), ANNOUNCED TODAY THAT IT HAS SIGNED A NATIONAL AGREEMENT WITH ELEVANCE HEALTH, INC. (NYSE: ELV), EFFECTIVE MAY 1, 2026, COVERING APPROXIMATELY 45.4 MILLION PEOPLE THROUGHOUT THE UNITED STATES, TO PROVIDE THE CNSIDE CEREBROSPINAL FLUID (CSF) TUMOR CELL ENUMERATION (TCE) ASSAY. THIS BRINGS CNSIDE CSF TCE ASSAY TOTAL CONTRACTED COVERAGE TO 126 MILLION PEOPLE.

PLUS THERAPEUTICS SECURES NATIONAL COVERAGE AGREEMENT WITH ELEVANCE HEALTH FOR CNSIDE CEREBROSPINAL FLUID ASSAY FOR METASTATIC CNS CANCER

MANAGEMENT TO UPDATE ON 2026 MID-YEAR PROGRESS, MILESTONES AND PROVIDE DETAILS ON ITS INTEGRATED CNS ONCOLOGY STRATEGY AND ARTIFICIAL INTELLIGENCE PLANS MANAGEMENT TO UPDATE ON 2026 MID-YEAR PROGRESS, MILESTONES AND PROVIDE DETAILS ON ITS INTEGRATED CNS ONCOLOGY STRATEGY AND ARTIFICIAL INTELLIGENCE PLANS

PLUS THERAPEUTICS TO PROVIDE BUSINESS UPDATE CALL ON JUNE 30, 2026

HOUSTON, JUNE 04, 2026 (GLOBE NEWSWIRE) -- CNSIDE DIAGNOSTICS, LLC, A WHOLLY OWNED SUBSIDIARY OF PLUS THERAPEUTICS, INC. (NASDAQ: PSTV) (PLUS OR THE COMPANY), A HEALTHCARE COMPANY ADVANCING PRECISION DIAGNOSTICS AND RADIOPHARMACEUTICALS FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY ANNOUNCES THAT ITS HOUSTON-BASED CLINICAL LABORATORY HAS RECEIVED ACCREDITATION FROM THE COLLEGE OF AMERICAN PATHOLOGISTS (CAP) FOLLOWING A RECENT ON-SITE INSPECTION CONDUCTED UNDER THE CAP LABORATORY ACCREDITATION PROGRAM. THE CAP LABORATORY ACCREDITATION PROGRAM IS INTERNATIONALLY RECOGNIZED AS THE GOLD STANDARD IN LABORATORY ACCREDITATION.

PLUS THERAPEUTICS ANNOUNCES CAP ACCREDITATION OF CNSIDE DIAGNOSTICS CLINICAL LABORATORY

PLUS AND HARVARD ANALYSIS SHOWS CNSIDE ENABLES EARLY DIAGNOSIS AND BETTER CLINICAL DECISION-MAKING REDUCING HEALTHCARE COSTS BY 40%

Plus Therapeutics, Inc.

PSTV

Price

Financial Reports

No items found.

Press Releases

Plus Therapeutics, Inc.

PSTV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PSTV